These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 28762136)

  • 1. Predicting Cortisol Exposure from Paediatric Hydrocortisone Formulation Using a Semi-Mechanistic Pharmacokinetic Model Established in Healthy Adults.
    Melin J; Parra-Guillen ZP; Hartung N; Huisinga W; Ross RJ; Whitaker MJ; Kloft C
    Clin Pharmacokinet; 2018 Apr; 57(4):515-527. PubMed ID: 28762136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and testing in healthy adults of oral hydrocortisone granules with taste masking for the treatment of neonates and infants with adrenal insufficiency.
    Whitaker MJ; Spielmann S; Digweed D; Huatan H; Eckland D; Johnson TN; Tucker G; Krude H; Blankenstein O; Ross RJ
    J Clin Endocrinol Metab; 2015 Apr; 100(4):1681-8. PubMed ID: 25646792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Absorption and tolerability of taste-masked hydrocortisone granules in neonates, infants and children under 6 years of age with adrenal insufficiency.
    Neumann U; Whitaker MJ; Wiegand S; Krude H; Porter J; Davies M; Digweed D; Voet B; Ross RJ; Blankenstein O
    Clin Endocrinol (Oxf); 2018 Jan; 88(1):21-29. PubMed ID: 28815660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paediatric population pharmacokinetic modelling to assess hydrocortisone replacement dosing regimens in young children.
    Michelet R; Melin J; Parra-Guillen ZP; Neumann U; Whitaker JM; Stachanow V; Huisinga W; Porter J; Blankenstein O; Ross RJ; Kloft C
    Eur J Endocrinol; 2020 Oct; 183(4):357-368. PubMed ID: 32621587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma, salivary and urinary cortisol levels following physiological and stress doses of hydrocortisone in normal volunteers.
    Jung C; Greco S; Nguyen HH; Ho JT; Lewis JG; Torpy DJ; Inder WJ
    BMC Endocr Disord; 2014 Nov; 14():91. PubMed ID: 25425285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immediate-release granule formulation of hydrocortisone, Alkindi®, for treatment of paediatric adrenal insufficiency (Infacort development programme).
    Porter J; Withe M; Ross RJ
    Expert Rev Endocrinol Metab; 2018 May; 13(3):119-124. PubMed ID: 30058902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving glucocorticoid replacement therapy using a novel modified-release hydrocortisone tablet: a pharmacokinetic study.
    Johannsson G; Bergthorsdottir R; Nilsson AG; Lennernas H; Hedner T; Skrtic S
    Eur J Endocrinol; 2009 Jul; 161(1):119-30. PubMed ID: 19383806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Achieving a physiological cortisol profile with once-daily dual-release hydrocortisone: a pharmacokinetic study.
    Johannsson G; Lennernäs H; Marelli C; Rockich K; Skrtic S
    Eur J Endocrinol; 2016 Jul; 175(1):85-93. PubMed ID: 27129362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic evidence for suboptimal treatment of adrenal insufficiency with currently available hydrocortisone tablets.
    Simon N; Castinetti F; Ouliac F; Lesavre N; Brue T; Oliver C
    Clin Pharmacokinet; 2010 Jul; 49(7):455-63. PubMed ID: 20528006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Replacement therapy of oral hydrocortisone in adrenal insufficiency: the influence of gastrointestinal factors.
    Lennernäs H; Skrtic S; Johannsson G
    Expert Opin Drug Metab Toxicol; 2008 Jun; 4(6):749-58. PubMed ID: 18611115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Weight-related dosing, timing and monitoring hydrocortisone replacement therapy in patients with adrenal insufficiency.
    Mah PM; Jenkins RC; Rostami-Hodjegan A; Newell-Price J; Doane A; Ibbotson V; Tucker GT; Ross RJ
    Clin Endocrinol (Oxf); 2004 Sep; 61(3):367-75. PubMed ID: 15355454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Variability in hydrocortisone plasma and saliva pharmacokinetics following intravenous and oral administration to patients with adrenal insufficiency.
    Thomson AH; Devers MC; Wallace AM; Grant D; Campbell K; Freel M; Connell JM
    Clin Endocrinol (Oxf); 2007 Jun; 66(6):789-96. PubMed ID: 17437510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioavailability of oral hydrocortisone in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
    Charmandari E; Johnston A; Brook CG; Hindmarsh PC
    J Endocrinol; 2001 Apr; 169(1):65-70. PubMed ID: 11250647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of Adrenal Crisis: Cortisol Responses to Major Stress Compared to Stress Dose Hydrocortisone Delivery.
    Prete A; Taylor AE; Bancos I; Smith DJ; Foster MA; Kohler S; Fazal-Sanderson V; Komninos J; O'Neil DM; Vassiliadi DA; Mowatt CJ; Mihai R; Fallowfield JL; Annane D; Lord JM; Keevil BG; Wass JAH; Karavitaki N; Arlt W
    J Clin Endocrinol Metab; 2020 Jul; 105(7):2262-74. PubMed ID: 32170323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic/Pharmacodynamic Evaluation of Hydrocortisone Therapy in Pediatric Patients with Congenital Adrenal Hyperplasia.
    Melin J; Parra-Guillen ZP; Michelet R; Truong T; Huisinga W; Hartung N; Hindmarsh P; Kloft C
    J Clin Endocrinol Metab; 2020 Mar; 105(3):. PubMed ID: 32052005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Usefulness of Time-Point Serum Cortisol and ACTH Measurements for the Adjustment of Glucocorticoid Replacement in Adrenal Insufficiency.
    Rousseau E; Joubert M; Trzepla G; Parienti JJ; Freret T; Vanthygem MC; Desailloud R; Lefebvre H; Coquerel A; Reznik Y;
    PLoS One; 2015; 10(8):e0135975. PubMed ID: 26317782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of oral hydrocortisone - Results and implications from a randomized controlled trial.
    Werumeus Buning J; Touw DJ; Brummelman P; Dullaart RPF; van den Berg G; van der Klauw MM; Kamp J; Wolffenbuttel BHR; van Beek AP
    Metabolism; 2017 Jun; 71():7-16. PubMed ID: 28521880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circadian hydrocortisone infusions in patients with adrenal insufficiency and congenital adrenal hyperplasia.
    Merza Z; Rostami-Hodjegan A; Memmott A; Doane A; Ibbotson V; Newell-Price J; Tucker GT; Ross RJ
    Clin Endocrinol (Oxf); 2006 Jul; 65(1):45-50. PubMed ID: 16817818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved cortisol exposure-time profile and outcome in patients with adrenal insufficiency: a prospective randomized trial of a novel hydrocortisone dual-release formulation.
    Johannsson G; Nilsson AG; Bergthorsdottir R; Burman P; Dahlqvist P; Ekman B; Engström BE; Olsson T; Ragnarsson O; Ryberg M; Wahlberg J; Biller BM; Monson JP; Stewart PM; Lennernäs H; Skrtic S
    J Clin Endocrinol Metab; 2012 Feb; 97(2):473-81. PubMed ID: 22112807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An oral multiparticulate, modified-release, hydrocortisone replacement therapy that provides physiological cortisol exposure.
    Whitaker M; Debono M; Huatan H; Merke D; Arlt W; Ross RJ
    Clin Endocrinol (Oxf); 2014 Apr; 80(4):554-561. PubMed ID: 23980724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.